Sartorius Unveils Upgraded BIOSTAT STR Single-Use Bioreactor Family, Enhancing Biologics Scalability

Pharmaceutical Technology USA

Overview

Sartorius Stedim Biotech has released an enhanced BIOSTAT STR single-use stirred-tank bioreactor family, featuring upgraded hardware, software, and new Flexsafe STR bags. This scalable system supports working volumes from 12.5 L to 2000 L, enabling linear scale-up and process transfer within weeks. The innovation significantly boosts efficiency and flexibility for biopharmaceutical manufacturing, from process development to commercial production.

In Depth

Background

The biopharmaceutical industry is continuously striving for accelerated development timelines and reduced manufacturing costs while maintaining stringent quality standards. Single-use technologies have emerged as a cornerstone in achieving these goals, offering benefits such as eliminating cleaning-in-place (CIP) and sterilization-in-place (SIP) processes, thereby reducing contamination risks and increasing operational flexibility. Sartorius Stedim Biotech, a leader in bioprocess solutions, has responded to these market demands by further advancing its flagship single-use bioreactor portfolio.

Key Findings / Results

Sartorius Stedim Biotech’s refreshed BIOSTAT STR bioreactor family introduces a comprehensive upgrade to its scalable single-use stirred-tank systems. The enhanced platform integrates state-of-the-art hardware, intuitive software, and newly optimized Flexsafe STR single-use bags. A critical advancement is the broad range of working volumes supported, spanning from 12.5 L for early-stage process development to 2000 L for large-scale commercial manufacturing. This extensive scalability ensures that processes developed at benchtop scales can be linearly and rapidly scaled up to production volumes. According to Sartorius, this linear scale-up and process transfer can be achieved in a matter of weeks, representing a significant reduction in time and cost compared to traditional stainless-steel systems. The new Flexsafe STR bags are designed to optimize cell growth and product yield by minimizing extractables and leachables, and ensuring robust performance across diverse biopharmaceutical applications.

• Expanded Volume Range: Supports operations from 12.5 L to 2000 L, catering to the full spectrum of bioprocess needs.
• Advanced Single-Use Technology: Incorporates new Flexsafe STR bags for superior cell culture performance and reduced contamination risk.
• Accelerated Scale-Up: Enables efficient, linear process transfer and scale-up in a significantly condensed timeframe of weeks.
• Integrated Platform: Features upgraded hardware, software, and consumables for seamless operation and enhanced data integrity.

Technical Significance & Outlook

The strengthening of the BIOSTAT STR family holds profound technical significance for contract development and manufacturing organizations (CDMOs) and biopharmaceutical manufacturers. Its enhanced scalability and rapid process transfer capabilities directly contribute to shortening drug development timelines and accelerating time-to-market for novel biologics. The adoption of advanced single-use technology inherently reduces capital expenditure, lowers operational costs associated with cleaning validation, and provides unparalleled manufacturing flexibility. This makes the system particularly well-suited for multi-product facilities, personalized medicine, and rapid response scenarios, such as pandemic vaccine production. Sartorius’s continued innovation in this space solidifies its leadership in the bioprocess industry and is expected to play a pivotal role in democratizing access to next-generation biopharmaceuticals by making their production more efficient and adaptable globally.